Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Immune NK T-cells may be therapeutic target for IPF

Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…

First patient enrolled in TETON PPF study of nebulized Tyvaso

The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…

Stem cell-Ofev combo eased lung scarring in mice

Treatment with mesenchymal stem cells (MSCs) bound to tiny vesicles loaded with Ofev’s active ingredient reduced lung inflammation and scarring while  promoting lung tissue repair in a mouse model of pulmonary fibrosis (PF), a study has shown. This combination strategy worked better than Ofev alone in both young…

Insilico’s AI-designed molecule enters Phase 2 testing

Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed using artificial intelligence (AI), as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patients have now received the first dose of oral INS018_055 in a randomized placebo-controlled Phase 2…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums